Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC ACTUAL-USE STUDIES ON PROPOSED LABELING

This article was originally published in The Tan Sheet

Executive Summary

OTC ACTUAL-USE STUDIES ON PROPOSED LABELING are essential to FDA because they "can provide actual data evaluating actual labels or label design variations," Louis Morris, PhD, of FDA's Division of Drug Marketing, Advertising and Communications, told a Sept. 9 meeting of a subcommittee of FDA's Nonprescription Drugs and Arthritis Advisory Committees.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS083233

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel